CompletedNot Applicable

Effects of Augmented Renal Clearance on Pharmacokinetic and Pharmacodynamic Properties of Levetiracetam in Subarachnoid Hemorrhage

United States15 participantsStarted 2016-01

Plain-language summary

This study evaluates the pharmacokinetic profile of levetiracetam in critically ill patients who have suffered a subarachnoid hemorrhage. The patients will be evaluated for development of augmented renal clearance and the effects and duration of effects this may have on levetiracetam clearance.

Who can participate

Age range18 Years – 89 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients diagnosed with non-traumatic subarachnoid hemorrhage requiring levetiracetam for seizure prophylaxis or treatment * Presentation to University of Colorado Hospital within 48 hours of subarachnoid hemorrhage * Adults ages 18 to 89 years * Anticipated length of stay ≥ 48 hours * Informed consent provided by the patient or patient's designated medical proxy Exclusion Criteria: * Pregnancy * Patients receiving renal replacement therapy * Brain death or imminent brain death expected ≤48 hours * Patient with history of nephrectomy or renal transplant

What they're measuring

Change in systemic levetiracetam clearance over time

Timeframe: 0-20 days

Trial details

NCT IDNCT02866877

SponsorUniversity of Colorado, Denver

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-06

View on ClinicalTrials.gov More Subarachnoid Hemorrhage trials